The UN General Assembly Resolutions on COVID-19: Solemn Assurances for Access to Health Technologies without an Action Plan
Policy Brief 81, July 2020
Nirmalya Syam
Policy Brief 81, July 2020
Nirmalya Syam
Intellectual Property, Innovation and Access to Health Products for COVID-19: A Review of Measures Taken by Different Countries
Policy Brief 80, June 2020
Nirmalya Syam
Policy Brief 80, June 2020
Nirmalya Syam
La pandemia de COVID-19: el fomento de la I+D y la gestión de la propiedad intelectual para acceder a diagnósticos, medicamentos y vacunas
Informe Sobre Políticas 73, Mayo 2020
Dr. Viviana Muñoz Tellez
Informe Sobre Políticas 73, Mayo 2020
Dr. Viviana Muñoz Tellez
La pandémie de COVID-19 : R&D et gestion de la propriété intellectuelle pour l’accès aux tests diagnostiques, aux médicaments et aux vaccins
Rapport sur les politiques 73, Mai 2020
Dr. Viviana Muñoz Tellez
Rapport sur les politiques 73, Mai 2020
Dr. Viviana Muñoz Tellez
Rethinking R&D for Pharmaceutical Products After the Novel Coronavirus COVID-19 Shock
Policy Brief 75, April 2020
Dr. Germán Velásquez
Policy Brief 75, April 2020
Dr. Germán Velásquez
The COVID-19 Pandemic: R&D and Intellectual Property Management for Access to Diagnostics, Medicines and Vaccines
Policy Brief 73, April 2020
Dr. Viviana Muñoz Tellez
Policy Brief 73, April 2020
Dr. Viviana Muñoz Tellez
USMCA debe ser enmendado para asegurar el acceso a medicamentos en México
Informe Sobre Políticas 64, Agosto de 2019
Maria Fabiana Jorge
Informe Sobre Políticas 64, Agosto de 2019
Maria Fabiana Jorge
The US-Mexico-Canada Agreement: Putting Profits Before Patients
Policy Brief 61, May 2019
Maria Fabiana Jorge
Policy Brief 61, May 2019
Maria Fabiana Jorge
The ‘obvious to try’ method of addressing strategic patenting: How developing countries can utilise patent law to facilitate access to medicines
Policy Brief 59, April 2019
Olga Gurgula
Policy Brief 59, April 2019
Olga Gurgula
Will the Amendment to the TRIPS Agreement Enhance Access to Medicines?
Policy Brief 57, January 2019
Carlos M. Correa
Policy Brief 57, January 2019
Carlos M. Correa
The Use of TRIPS Flexibilities for the Access to Hepatitis C Treatment
Policy Brief 54, October 2018
Germán Velásquez
Policy Brief 54, October 2018
Germán Velásquez
The International Debate on Generic Medicines of Biological Origin
Policy Brief 50, August 2018
Germán Velásquez
Policy Brief 50, August 2018
Germán Velásquez
The Need to Avoid “TRIPS-Plus” Patent Clauses in Trade Agreements
Policy Brief 37, March 2017
Martin Khor
Policy Brief 37, March 2017
Martin Khor
